Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine,… read more.
Mallinckrodt Plc announced publication of findings from a medical chart study to assess the real-world use of terlipressin and other vasopressors in hospitalized patients with hepatorenal syndrome type… read more.
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine,… read more.
Otsuka Pharmaceutical has announced positive top-line results from two, six-week, phase III clinical trials that evaluated the efficacy, safety and tolerability of oral EB 1020 (centanafadine), a novel… read more.
Viela Bio announced that the FDA has approved Uplizna (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive as… read more.
Impel NeuroPharma announced positive results from “STOP 301” (Safety and Tolerability of POD-DHE), the Company’s pivotal Phase III, open-label study of the safety and tolerability of INP 104… read more.
AbbVie announced new long-term results showing that once-daily Rinvoq (upadacitinib) continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the… read more.
Fulcrum Therapeutics, Inc. announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19 . Fulcrum has submitted an investigational new drug (IND) application to support… read more.
Mallinckrodt Plc announced that Stratatech, a Mallinckrodt company, has completed its rolling submission of a Biologics License Application (BLA) to the FDA for StrataGraft, a regenerative skin tissue… read more.
The first patient dose has been delivered in SURPASS-CVOT, the phase III cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company’s investigational dual GIP and GLP-1 receptor agonist…. read more.
Astellas Pharma Inc. announced results from the Phase III DOLOMITES study , evaluating the efficacy and safety of roxadustat compared with darbepoetin alfa for the treatment of anemia… read more.
The European Medicines Agency (EMA) reports that Gilead Sciences has submitted its marketing application seeking conditional approval of antiviral remdesivir for the treatment of COVID-19. Since the EU… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
